For Researchers

Use the resources below to stay informed on reporting obligations, access training tools, and get support for clinical trial conduct at your cancer centre.



Trial Portfolio-header-two

Trial Portfolio-header-three

Trial Portfolio

Patient & Public Involvement-header-two

Patient & Public Involvement-header-three

CRAFT - DCT-header-two

CRAFT - DCT-header-three

G.A.P.P. Webinar Series-header-two

G.A.P.P. Webinar Series-header-three

impACCT Virtual Rounds-header-two

impACCT Virtual Rounds-header-three

Reporting Obligations-header-two

Reporting Obligations-header-three

Recruitment Best Practices Inventory-header-two

Recruitment Best Practices Inventory-header-three

Biospecimen SOPs-header-two

Biospecimen SOPs-header-three

CTMS-EDGE Support-header-two

CTMS-EDGE Support-header-three

Ask Me Campaign Materials-header-two

Ask Me Campaign Materials-header-three



Trial Portfolio


3CTN supports a portfolio of academic clinical trials that reflect the priorities of clinicians, researchers, patients, ministries of health and funders. Scientific oversight will be provided by the Portfolio Committee (PC) and management of the day-to-day operations is provided by the 3CTN Coordinating Centre. Academically sponsored trials that are included on the portfolio are eligible for 3CTN support.

3CTN aims to assist both clinicians/researchers and patients in finding cancer clinical trials that may be of benefit. Patients that are interested in participating in a clinical trial must contact their healthcare provider for details, but may wish to search the 3CTN Portfolio to know which trials are open to accrual at their local centre.

3CTN Portfolio Trial Listing

3CTN has created an interactive repository of trials to help you easily navigate through all past and present Portfolio trials.

View the 3CTN Portfolio Trial Listing

Watch a quick tutorial on how to use the 3CTN Portfolio Trial Listing here.

Learn about the Portfolio

Portfolio Application

Portfolio Trial Eligibility

  • An eligible trial must meet the following criteria:
    • Interventional oncology trial;
    • Academically sponsored (Clinical Trial Applications held by academic institution);
    • Open to multiple Canadian sites;
    • Funded independently of 3CTN;
    • Peer reviewed by external reviewers.
  • For additional details, see the Trial Eligibility Criteria and Guidelines.

To submit a trial for consideration for the 3CTN Portfolio, complete the Application Form and submit to <>. Trials will be assessed according to the Portfolio Process Map. If your cancer centre is using EDGE please submit your application through EDGE following these steps

If you have recently submitted a trial for review, please see the Portfolio Application Status Update Summary for a list of studies submitted to 3CTN for review and approval.

Facilitated Peer Review

The 3CTN Coordinating Centre can help facilitate peer review for an un-reviewed trial. Please see the documents listed below for further details:

Portfolio Assessment

Once a trial has been assessed and accepted on to the 3CTN Portfolio, a Network centre that has the opened the trial to accrual is eligible to receive per case funding (PCF) for those patients recruited above the centre’s established PCF trigger*

*as defined within individual contractual agreements between 3CTN and the Network centre site.

Per Case Funding Amounts

The PCF amount for 2018-2022 associated with each complexity rating:

Trial Complexity Score PCF Amount ($)**
0-3 (Low) 500
4-6 (Standard) 850
≥ 7 (High)

**PCF distribution is subject to available funding

Incentive Based Funding

3CTN’s funding model has been updated to include Incentive Based Funding (IBF) for Year 7 (April 1, 2020-March 31, 2021) and Year 8 (April 1, 2021-March 31, 2022).IBF rates are subject to funding availability. Please refer to the Incentive Based Funding Process for IBF factors and definitions. Also see the Incentive Based Funding FAQs.

Portfolio Impact

Adapted from published literature, 3CTN created categories to describe the mix of trials that make up the Network’s Portfolio.  The customized framework developed with the Portfolio Committee’s input was derived from “The Importance of Doing Trials Right While Doing the Right Trials” paper (Dilts et. Al.) and can allow for analyses based on a standardized set of Study Criteria as well as defined Impact on Patient Population and Innovativeness (see below).

Results from periodic review will enable assessments of the different types of studies being undertaken at a given point, trends and changes over time as well as help articulate the overall impact of the Portfolio for funders and other stakeholders.

View an interactive report on the outcomes of 3CTN’s Portfolio Impact Analysis.

Search the Portfolio

Cancer Clinical Trial Maps